PharmaCyte Biotech, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2016. Although the request metadata refers to 2015 Q4, this filing reports FY2016 and includes FY2015 comparative figures, which were restated.
Business context
PharmaCyte is a pre-revenue, clinical-stage biotechnology company developing cancer and diabetes treatments using its Cell-in-a-Box cellulose-based live-cell encapsulation technology. Its principal program is targeted chemotherapy for advanced pancreatic cancer; other programs include malignant ascites, diabetes, and preliminary cannabinoid-based cancer research. No product candidate has regulatory marketing approval.
Key financial metrics
| Metric | FY ended April 30, 2016 | FY ended April 30, 2015 (restated) |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses / operating loss | $6.07 million | $13.26 million |
| Net loss | $6.06 million | $9.93 million |
| Basic and diluted loss per share | $0.01 | $0.01 |
| Cash from operations | $(4.35) million | $(4.56) million |
| Cash at year-end | $1.92 million | $2.70 million |
| Total assets | $7.16 million | $9.30 million |
| Total liabilities | $0.64 million | $1.52 million |
| Stockholders’ equity | $6.52 million | $7.78 million |
There was no revenue or gross profit, so operating or gross margins are not meaningful. The balance sheet listed no long-term liabilities; current liabilities comprised accounts payable, accrued expenses, and a license obligation. The company reported an accumulated deficit of $84.69 million. It had no cash flow from investing activities in FY2016 or FY2015.
Changes versus the prior year
- Operating expenses fell 54% to $6.07 million, chiefly because research and development expense declined from $3.48 million to $1.41 million and compensation expense declined from $6.49 million to $1.87 million, including lower stock-based compensation.
- Net loss narrowed by $3.86 million. FY2015 included a $3.34 million gain on settlements, while FY2016 other income was only $9,349.
- Operating cash use eased to $4.35 million from $4.56 million, but financing proceeds of $3.57 million did not fully offset operating cash burn; year-end cash decreased by $0.78 million.
- Common shares outstanding rose from 732.8 million to 781.2 million during the year. Potential options and warrants totaling 153.0 million shares were excluded from diluted loss per share as anti-dilutive.
Outlook, risks, and unusual items
- Funding and liquidity: Management said year-end cash, together with anticipated stock sales, was expected to fund operations through fiscal year-end 2017; elsewhere the filing describes funding through July 31, 2017. It also reported approximately $2.2 million in cash as of July 28, 2016 and current cash spending of about $150,000 per month. These are estimates, not assurances. The company has no operating revenue, expects further losses, and depends on external financing. It stated it was not eligible to use Form S-3 for a primary offering at filing.
- Clinical plans: Subject to FDA approval, the company planned a randomized Phase 2b pancreatic cancer trial comparing its encapsulated-cell/low-dose ifosfamide therapy with gemcitabine in a defined post-treatment patient group. The trial’s timing was prospective, not a completed milestone. A malignant-ascites trial was contemplated for 2017 if preclinical results and regulatory approval supported it. Diabetes work remained preclinical; cannabinoid work was preliminary.
- Evidence limitations: Earlier European pancreatic cancer trials were small and single-arm. The company reported median survival of 39 weeks and a 36% one-year survival rate in the Phase 1/2 study, and 40 weeks and 23% in Phase 2. These results were not statistically conclusive and cannot establish comparative efficacy; the Phase 2 trial’s higher ifosfamide dose was associated with more toxicity.
- Going-concern and execution risks: The filing describes substantial ongoing financing needs and warns that insufficient funding could delay or prevent planned trials. The company relies heavily on third parties, especially Austrianova for encapsulation/manufacturing, and on a small number of key consultants. It has no sales infrastructure.
- Controls and restatement: Management and the auditor concluded internal control over financial reporting was ineffective at April 30, 2016, citing governance, documentation, segregation-of-duties, communication, and IT-control weaknesses. Prior financial statements were restated for accounting errors involving warrants, shares, and related items. The auditor gave an adverse opinion on internal controls but an unqualified opinion on the FY2016 financial statements.
- Intellectual property and dilution: Licensed cytochrome P450-related patents were scheduled to expire March 27, 2017. The company issued 42.9 million shares for cash during FY2016 and reported 848.1 million shares outstanding as of July 29, 2016. Further equity funding could dilute existing holders.
- Subsequent financing disclosure: The filing reports approximately $1 million raised through at-the-market transactions from May 1 to July 29, 2016 in one section, but approximately $1.33 million from 66.8 million shares in its subsequent-events note. It also reports completing the remaining $150,000 Cannabis license upfront payment in May and June 2016.
Important facts for investors to verify
- Current cash, monthly burn, financing raised after year-end, and whether the stated runway assumptions remain valid.
- FDA status, trial authorization, site activation, enrollment, and funding for the planned pancreatic cancer Phase 2b trial.
- Progress and regulatory plans for the ascites, diabetes, and cannabinoid programs, which were at earlier development stages.
- Remediation of the disclosed material weaknesses and whether subsequent filings require further corrections or restatements.
- Patent coverage and strategy following the scheduled March 2017 expiration of the cited cytochrome P450 patents.
- Actual and potential share dilution, including outstanding options and warrants, and the company’s ability to access capital markets.
- Commercial and manufacturing terms, milestone obligations, and reliance on Austrianova and other related or third-party service providers.